Autopsy report · NCT01650805
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Cause of deathSafety
“Study terminated based on evaluation of safety data.”
Life of this trial
- Registered 1 month after it had already started.
- Ran for about 1 year 4 months before it stopped.
- 307 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Ariad Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- ponatinib; imatinib (Gleevec/ Glivec)
- Participants
- 307
- Sites
- 170
- Countries
- Australia, Austria, Belgium, Canada, Czechia, Finland, France, Germany, Hong Kong, Italy, Netherlands, New Zealand and more
Trials that died the same way
- Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
“This study was terminated based on preliminary safety data.” - A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
“The study terminated for safety reasons” - Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
“This study was terminated for reasons not related to efficacy or safety” - Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus
“The study was terminated in the interest of patient safety.” - Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
“Study was terminated due to safety reason.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.